Abstract 6002: Biodegradable-polymer Infinnium Paclitaxel-eluting And Supralimus Sirolimus-eluting Stents Reduce Neointimal Proliferation In Patients At Low Risk Of Restenosis: Findings From The 3-arm Paint Randomized Controlled Trial
Background: The benefit of drug-eluting stents for patients at low risk for restenosis remains debatable. We evaluated the 9-month angiographic outcomes of patients with reduced risk of restenosis treated with two new formulations of biodegradable-polymer drug-eluting stents (with paclitaxel or sirolimus).
Methods: The PAINT trial randomized patients with de novo lesions to treatment with a biodegradable-polymer paclitaxel-eluting, a biodegradable-polymer sirolimus-eluting, or a control bare metal stent (2:2:1 ratio). The present study population comprises a subset of 145 patients (control=31 pts; paclitaxel=59 pts; sirolimus=55 pts) included in the PAINT, who were non diabetics and received either large (3.5 mm) or short (19 mm) stents. Follow-up control angiography was obtained at 9 months after the index procedure.
Results: There were no significant differences in baseline or procedural differences among the study groups. Overall, mean age was 60±11 years, 67% were men. The left anterior descending was treated in 50% of the cases. The table⇓ summarizes the angiographic characteristics of patients treated with bare stents, paclitaxel-eluting or sirolimus-eluting stents.
Conclusions: This subgroup analysis from the PAINT randomized trial shows that, in comparison with bare stents, both formulations of biodegradable-polymer paclitaxel-eluting and sirolimus-eluting stents are effective in reducing neointimal proliferation and binary restenosis at 270 days for low risk patients.